mavacamten

Mavacamten is a first-in-class, oral small molecule that acts as a selective allosteric inhibitor of cardiac myosin ATPase. It is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. By binding to cardiac myosin, mavacamten reduces the number of actin-myosin cross-bridges during cardiac muscle contraction, thereby decreasing excessive contractility and left ventricular outflow tract obstruction characteristic of HCM. This results in improved heart relaxation and filling, reduced obstruction, and enhanced exercise capacity. Mavacamten was developed by MyoKardia (now part of Bristol Myers Squibb) and is marketed under the brand name Camzyos[2][4][6][8].

Brand names

Camzyos

Other names

MYK-461MYK461MYK 461mavacamten